Therapeutic compositions comprising cannabidiol and corticosteroids

1. A composition formulated for oral administration comprising:

i) a tetrahydrocannabinoid compound or functionally equivalent synthetic derivative thereof selected from the group consisting of delta-9 tetrahydrocannabinol (THC), delta-8 tetrahydrocannabinol (D8-THC), tetrahydrocannabinol acid (THCA), tetrahydrocannabivarin (THCV), tetrahydrocannabivarin acid (THCVA), nabilone, rimonabant (SR141716), JWH-018, JWH-073, CP-55940, dimethylheptylpyran, HU-210, HU-331, SR144528, WIN 55,212-2, JWH-133, levonantradol and AM-2201;

ii) a second cannabinoid or functionally equivalent synthetic derivative thereof selected from the group consisting of cannabidiol (CBD), cannabidiol acid (CBDA), cannabinol (CBN), cannabigerol (CBG), cannabigerol acid (CBGA), cannabidivarin (CBDV), cannabidivarin acid (CBDVA), cannabinovarin (CBNV), cannabigerovarin (CBGV), cannabichromene (CBC), JWH-018, JWH-073, JWH-398, JWH-200, JWH-081, 4-methyl-JWH-073, JWH-015, JWH-122, JWH-220, JWH-019, JWH-007, JWH-250, JWH-203, RCS-4, AM-694, WIN 48,098, CP 47,497-C8, CP 47,497 and HU-210; and

iii) a corticosteroid,

wherein the composition is a wafer that exhibits a T max , of less than 10 minutes, said wafer being formed by combining the tetrahydrocannabinoid, second cannabinoid and corticosteroid with an aqueous solution comprising at least about 30 to 80 wt % of a film forming agent selected from pullulan, or a mixture of pullulan with one or more other film forming agents to form a gel that is spread and dried to form the wafer.

2. The composition of claim 1 , comprising the tetrahydrocannabinoid in an amount in the range of about 1-10% by wt, the second cannabinoid in an amount in the range of about 1-10% by wt and the corticosteroid in an amount in the range of about 0.01-10% by wt.

3. The composition of claim 2 , comprising the tetrahydrocannabinoid in an amount in the range of about 4-6% by wt, the second cannabinoid in an amount in the range of about 4-6% by wt and the corticosteroid in au amount in the range of about 0.01-1% by wt.

4. The composition of claim 1 , wherein the corticosteroid is selected from the group consisting of clobetasol, betamethasone, haltobetasol, fluocinonide, flurandrrenolide, mometasone, diflorasone, halcinonide, desoximetasone and fluticasone.

5. The composition of claim 1 , comprising THC, cannabidiol and mometasone.

6. The composition of claim 1 , wherein the other film forming agent is selected from the group consisting of polyvinyl alcohol, carboxymethylcellulose, carrageenan, guar gum, gelatin, xanthan gum, agar and locust bean gum.

7. A method of treating psoriasis and related conditions in a mammal comprising administering to the mammal a composition as defined in claim 1 .

8. The method of claim 7 , wherein the composition comprises the tetrahydrocannabinoid in an amount in the range of about 1-10% by wt, the second cannabinoid in an amount in the range of about 1-10% by wt and the corticosteroid in an amount in the range of about 0.01-10% by wt.

9. The method of claim 7 , wherein the corticosteroid is selected from the group consisting of clobetasol, betamethasone, haltobetasol, fluocinonide, flurandrrenolide, mometasone, diflorasone, halcinonide, desoximetasone and fluticasone.

10. The method of claim 7 , wherein the composition is orally administered.

11. The method of claim 7 , wherein the composition comprises THC, cannabidiol and mometasone.

12. The composition of claim 1 , wherein said other film-forming agent is at least one of polyvinyl alcohol, carrageenan, guar gum, xanthan gum and locust bean gum.

13. The composition of claim 1 , which comprises polyethylene glycol in an amount of less than about 5 wt %.

14. The composition of claim 1 , wherein the wafer exhibits a dissolution rate of at least about 2 milligrams/second in an aqueous environment.